{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:08:29Z","timestamp":1765289309872,"version":"3.46.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016939","name":"Myriad Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016939","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ucl.2025.09.013","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:36:38Z","timestamp":1761827798000},"page":"171-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current and Upcoming Trials in Localized Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Landan P.","family":"MacDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian F.","family":"Chapin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025. CA A","volume":"75","author":"Siegel","year":"2025","journal-title":"Cancer J Clinicians"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"17","key":"10.1016\/j.ucl.2025.09.013_bib4","first-page":"1884","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Orthod"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.013_bib5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ucl.2025.09.013_bib6","first-page":"2325","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Orthod"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.013_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(25)00034-8","article-title":"Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium","volume":"26","author":"Kishan","year":"2025","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.013_bib8","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.eururo.2024.08.030","article-title":"Radical prostatectomy versus stereotactic radiotherapy for clinically localised prostate cancer: results of the PACE-A randomised trial","volume":"86","author":"Van As","year":"2024","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.ucl.2025.09.013_bib9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"Van As","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.013_bib10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","article-title":"Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: results from the PROSINT phase 2 randomized clinical trial","volume":"7","author":"Greco","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ucl.2025.09.013_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109503","article-title":"Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion \u2013 results from the 2SMART phase 2 trial","volume":"181","author":"Ong","year":"2023","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.013_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.013_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ucl.2025.09.013_bib14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fonc.2014.00240","article-title":"Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-9-1","article-title":"Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study","volume":"9","author":"Katz","year":"2014","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.013_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/PPO.0000000000000209","article-title":"Stereotactic body radiation therapy for localized prostate cancer","volume":"22","author":"Lischalk","year":"2016","journal-title":"Cancer J"},{"issue":"17","key":"10.1016\/j.ucl.2025.09.013_bib17","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"1131","key":"10.1016\/j.ucl.2025.09.013_bib18","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210670","article-title":"Proton therapy for prostate cancer: current state and future perspectives","volume":"95","author":"Wu","year":"2022","journal-title":"Br J Radiol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.013_bib19","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.ijrobp.2024.05.014","article-title":"Stereotactic body proton therapy versus conventionally fractionated proton therapy for early prostate cancer: a randomized, controlled, phase 3 trial","volume":"120","author":"Toesca","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.013_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.clgc.2020.08.009","article-title":"Overall survival after treatment of localized prostate cancer with proton beam therapy, external-beam photon therapy, or brachytherapy","volume":"19","author":"Liu","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.013_bib21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijrobp.2024.08.012","article-title":"Prostate advanced radiation technologies investigating quality of life (PARTIQoL): phase III randomized clinical trial of proton therapy vs. IMRT for localized prostate Cancer","volume":"120","author":"Efstathiou","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.013_bib22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2017.03.028","article-title":"Cost of new technologies in prostate cancer treatment: systematic review of costs and cost effectiveness of robotic-assisted laparoscopic prostatectomy, intensity-modulated radiotherapy, and proton beam therapy","volume":"72","author":"Schroeck","year":"2017","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.ucl.2025.09.013_bib23","first-page":"1823","article-title":"Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer","volume":"36","author":"Pan","year":"2018","journal-title":"J Clin Orthod"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.013_bib24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.013_bib25","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.013_bib26","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.013_bib27","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.02.073","article-title":"Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer","volume":"72","author":"Al-Mamgani","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.013_bib28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ucl.2025.09.013_bib30","first-page":"787","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijrobp.2018.01.040","article-title":"Determination of intrafraction prostate motion during external beam radiation therapy with a transperineal 4-dimensional ultrasound real-time tracking system","volume":"101","author":"Sihono","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ucl.2025.09.013_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.909402","article-title":"Clinical utility of a 1.5 T magnetic resonance imaging-guided linear accelerator during conventionally fractionated and hypofractionated prostate cancer radiotherapy","volume":"12","author":"Turkkan","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.013_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.10819","article-title":"Safety and tolerability of online adaptive high-field magnetic resonance\u2013guided radiotherapy","volume":"7","author":"Westerhoff","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib34","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/s12885-021-08281-x","article-title":"Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.ucl.2025.09.013_bib35","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.2018.3712","article-title":"Prostate-specific antigen\u2013based screening for prostate cancer: evidence report and systematic review for the US preventive services task force","volume":"319","author":"Fenton","year":"2018","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ucl.2025.09.013_bib36","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US preventive services task force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ucl.2025.09.013_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107168","article-title":"Study protocol for a prospective, multi-centered randomized controlled trial comparing pelvic fascia-sparing radical prostatectomy with conventional robotic-assisted prostatectomy: the PARTIAL trial","volume":"128","author":"Stangl-Kremser","year":"2023","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.013_bib38","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bju.15195","article-title":"Retzius-sparing robot-assisted radical prostatectomy improves early recovery of urinary continence: a randomized, controlled, single-blind trial with a 1-year follow-up","volume":"126","author":"Qiu","year":"2020","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.013_bib39","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.euo.2021.02.005","article-title":"A randomised controlled trial to assess the benefit of posterior rhabdosphincter reconstruction in early urinary continence recovery after robot-assisted radical prostatectomy","volume":"5","author":"Salazar","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.013_bib40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11701-019-00972-9","article-title":"A single-center, retrospective review of robot-assisted laparoscopic prostatectomy with and without cryopreserved umbilical cord allograft in improving continence recovery","volume":"14","author":"Ahmed","year":"2020","journal-title":"J Robotic Surg"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.013_bib41","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/JU.0000000000001845","article-title":"The duration of antibiotics prophylaxis at the time of catheter removal after radical prostatectomy: clinically integrated, cluster, randomized trial","volume":"206","author":"Ehdaie","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.013_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-025-01004-4","article-title":"5G-remote radical prostatectomy under novel robotic systems: a prospective comparative cohort study with local surgeries","author":"Ye","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.prro.2023.09.007","article-title":"Radiation therapy summary of the AUA\/ASTRO guideline on clinically localized prostate cancer","volume":"14","author":"Deville","year":"2024","journal-title":"Practical Radiation Oncology"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.013_bib45","first-page":"1234","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Orthod"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.013_bib46","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","article-title":"Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial","volume":"79","author":"Lestingi","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.013_bib47","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.euo.2021.03.006","article-title":"Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial","volume":"4","author":"Touijer","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.013_bib48","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2024.10.006","article-title":"Pelvic lymph node dissection in prostate cancer: update from a randomized clinical trial of limited versus extended dissection","volume":"87","author":"Touijer","year":"2025","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.013_bib49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.eururo.2024.12.001","article-title":"Oncological benefits of extended pelvic lymph node dissection: more fog or clarity to the debate?","volume":"87","author":"Roberts","year":"2025","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.013_bib50","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.21037\/tcr-23-2406","article-title":"A narrative clinical trials review in the realm of focal therapy for localized prostate cancer","volume":"13","author":"Lazarovich","year":"2024","journal-title":"Transl Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/cancers17010099","article-title":"Current status of neoadjuvant treatment before surgery in high-risk localized prostate cancer","volume":"17","author":"G\u00f3mez Rivas","year":"2024","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.013_bib52","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.013_bib53","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.013_bib54","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2019.11.415","article-title":"Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial","volume":"106","author":"Joseph","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.013_bib55","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijrobp.2023.08.046","article-title":"Trimodality therapy with iodine-125 brachytherapy, external beam radiation therapy, and short- or long-term androgen deprivation therapy for high-risk localized prostate cancer: results of a multicenter, randomized phase 3 trial (TRIP\/TRIGU0907)","volume":"118","author":"Yorozu","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ucl.2025.09.013_bib56","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ucl.2025.09.013_bib57","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.013_bib58","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ucl.2025.09.013_bib59","first-page":"3042","article-title":"Cancer and leukemia group B 90203 (alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Orthod"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.013_bib60","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2019.08.010","article-title":"Docetaxel versus surveillance after radical radiotherapy for intermediate- or high-risk prostate cancer\u2014results from the prospective, randomised, open-label phase III SPCG-13 trial","volume":"76","author":"Kellokumpu-Lehtinen","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.013_bib61","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2019.12.020","article-title":"Veterans affairs cooperative studies program study #553: chemotherapy after prostatectomy for high-risk prostate carcinoma: a phase III randomized study","volume":"77","author":"Lin","year":"2020","journal-title":"Eur Urol"},{"issue":"14","key":"10.1016\/j.ucl.2025.09.013_bib62","first-page":"1159","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Orthod"},{"issue":"26","key":"10.1016\/j.ucl.2025.09.013_bib63","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.21.00596","article-title":"Radiation and androgen deprivation therapy with or without docetaxel in the management of nonmetastatic unfavorable-risk prostate cancer: a prospective randomized trial","volume":"39","author":"D\u2019Amico","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.013_bib64","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2023.04.024","article-title":"Androgen deprivation and radiotherapy with or without docetaxel for localized high-risk prostate cancer: long-term follow-up from the randomized NRG oncology RTOG 0521 Trial","volume":"84","author":"Sartor","year":"2023","journal-title":"Eur Urol"},{"issue":"10071","key":"10.1016\/j.ucl.2025.09.013_bib65","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ucl.2025.09.013_bib66","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ucl.2025.09.013_bib67","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ucl.2025.09.013_bib68","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","article-title":"Results after four years of screening for prostate cancer with PSA and MRI","volume":"391","author":"Hugosson","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ucl.2025.09.013_bib69","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib70","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000002182","article-title":"Why does magnetic resonance imaging-targeted biopsy miss clinically significant cancer?","volume":"207","author":"Williams","year":"2022","journal-title":"J Urol"},{"issue":"18","key":"10.1016\/j.ucl.2025.09.013_bib71","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1002\/cncr.34355","article-title":"Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions","volume":"128","author":"Fang","year":"2022","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.013_bib72","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.euf.2017.11.010","article-title":"Prostate magnetic resonance imaging interpretation varies substantially across radiologists","volume":"5","author":"Sonn","year":"2019","journal-title":"European Urology Focus"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.013_bib73","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","article-title":"Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE)","volume":"84","author":"Surasi","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib74","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with18 F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"issue":"10231","key":"10.1016\/j.ucl.2025.09.013_bib75","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.013_bib76","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jamaoncol.2024.3196","article-title":"Fluorine-18 prostate-specific membrane antigen\u20131007 PET\/CT vs multiparametric MRI for locoregional staging of prostate cancer","volume":"10","author":"Mookerji","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ucl.2025.09.013_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/S0302-2838(24)00414-7","article-title":"DEPROMP-study: PSMA-PET\/CT prior to prostate biopsy: enhancing prostate cancer detection and personalized management","volume":"85","author":"Krausewitz","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.013_bib78","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2023.11.008","volume":"7","author":"Buteau","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2025.09.013_bib79","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.21037\/tau-22-708","article-title":"68Ga-PSMA-PET\/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study","volume":"12","author":"Gondoputro","year":"2023","journal-title":"Transl Androl Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib80","doi-asserted-by":"crossref","first-page":"34.e27","DOI":"10.1016\/j.urolonc.2013.01.006","article-title":"High-resolution transrectal ultrasound: pilot study of a novel technique for imaging clinically localized prostate cancer","volume":"32","author":"Pavlovich","year":"2014","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.013_bib81","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1097\/JU.0000000000001639","article-title":"Micro-ultrasound\u2013guided vs multiparametric magnetic resonance imaging-targeted biopsy in the detection of prostate cancer: a systematic review and meta-analysis","volume":"205","author":"Sountoulides","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.013_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106618","article-title":"Optimization of prostate biopsy - micro-Ultrasound versus MRI (OPTIMUM): a 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer","volume":"112","author":"Klotz","year":"2022","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.013_bib83","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.013_bib84","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2023.04.010","article-title":"Genomic classifier performance in intermediate-risk prostate cancer: results from NRG oncology\/RTOG 0126 randomized phase 3 trial","volume":"117","author":"Spratt","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.013_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49964-7","article-title":"Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer","volume":"9","author":"Carm","year":"2019","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.ucl.2025.09.013_bib86","first-page":"1474","article-title":"Molecular biomarkers in localized prostate cancer: ASCO guideline","volume":"38","author":"Eggener","year":"2020","journal-title":"J Clin Orthod"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:04:59Z","timestamp":1765289099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014325000965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0094014325000965"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.013","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and Upcoming Trials in Localized Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}